GlassScriptPhysician profile
John M Rainey
NPI 1073724514
$3,092.44
in general payments reported to CMS, 2019-2025
30 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $251 · 2021: $435 · 2022: $382 · 2023: $268 · 2024: $435 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $458.07 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $401.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $367.43 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $305.03 | 2019-2025 | Jardiance |
| Abbvie INC. | $283.25 | 2021-2025 | |
| Mylan Specialty L.P. | $185.85 | 2019-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.14 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $126.81 | 2019-2022 | |
| Zimmer Biomet Holdings, INC. | $107.63 | 2022 | |
| Janssen Pharmaceuticals, INC | $77.21 | 2019-2022 | |
| Inari Medical, INC. | $65.15 | 2020 | |
| Esperion Therapeutics, INC. | $61.23 | 2020-2021 | |
| Glaxosmithkline, LLC. | $60.30 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $55.55 | 2024-2025 | |
| Medtronic Vascular, INC. | $46.01 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $35.34 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $30.68 | 2023-2025 | |
| Amgen INC. | $30.67 | 2025 | Repatha, Otezla |
| Lundbeck LLC | $30.65 | 2025 | Rexulti |
| Bioventus LLC | $27.31 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $24.41 | 2019 | |
| Amarin Pharma, INC. | $22.54 | 2019-2020 | |
| Allergan, INC. | $18.14 | 2019 | |
| Viatris Specialty LLC | $18.11 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $18.10 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.09 | 2025 | Rexulti |
| Exact Sciences Corporation | $16.92 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $16.83 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.79 | 2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $14.21 | 2025 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rainey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.